Moroles Investments, LLC

Moroles Investments, LLC specializes in mobility aids and patient care devices. Their portfolio includes manual and powered solutions like commodes for incontinence care, sliding transfer boards to assist patients moving between surfaces, bathing stretchers for safe hygiene procedures, electromechanical transport trolleys for moving patients or equipment, and reclining chairs for patient comfort and positioning. These devices are designed to improve patient mobility, safety, and clinical workflow efficiency in healthcare settings.

Moroles Investments, LLC is based in the United States. Their devices are engineered and marketed primarily for use within the U.S. healthcare environment, where they must comply with applicable FDA regulations and standards. The company’s focus is on addressing mobility and transfer needs in clinical, home care, and assisted living settings across the country.

Moroles Investments, LLC’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. The UDI system ensures traceability and transparency for regulated medical devices in the U.S., allowing healthcare providers, regulators, and other stakeholders to identify and verify specific products. This listing is required for Class I and Class II devices to meet compliance requirements.

Moroles Investments, LLC’s devices fall under two FDA classification categories: Class I and Class II. Class I devices generally pose minimal risk and are subject to general controls, while Class II devices require additional performance standards or special controls due to moderate risk. The classification depends on factors like the device’s intended use, potential hazards, and the body system it interacts with, as outlined in the FDA’s regulatory framework.

Certain devices in Moroles Investments, LLC’s portfolio are classified as Class II because they involve moderate risk to patients or users. For example, electromechanical transport trolleys or powered mobility aids may require additional controls to ensure safety, performance, and effectiveness in clinical use. The FDA assigns Class II status when general controls (like manufacturing practices and labeling) are insufficient to mitigate risks, necessitating special controls such as performance standards or post-market surveillance to maintain safety and reliability.